Want to see HK:1498 full AI Analyst Report?
1498 Stock Chart & Stats
HK$0.35
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$0.35
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.23 - HK$0.44
Previous CloseN/A
Volume23.50K
Average Volume (3M)30.71K
Market Cap
HK$123.04M
Enterprise ValueHK$517.12M
Total Cash (Recent Filing)HK$12.23M
Total Debt (Recent Filing)HK$370.62M
Price to Earnings (P/E)―
Beta0.29
Next Earnings
Mar 31, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.48%
Share Statistics
EPS (TTM)-0.06
Shares Outstanding535,897,640
10 Day Avg. Volume2,600
30 Day Avg. Volume30,708
Financial Highlights & Ratios
PEG Ratio0.68
Price to Book (P/B)1.14
Price to Sales (P/S)0.44
P/FCF Ratio5.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginsA gross margin near 53% indicates the company retains meaningful value after product costs, supporting reinvestment and channel development. Although bottom-line losses persist, this margin profile provides a stronger base for any future revenue stabilization or cost improvements.
Positive Cash GenerationPositive operating and free cash flow across four recent years shows that the business has generated cash despite reported losses. This supports ongoing operations and provides some internal funding capacity, although the sharp 2025 decline means the strength is not yet fully consistent.
Integrated Chinese Medicine PlatformPuraPharm combines proprietary Chinese medicine products with manufacturing, commercialization, and distribution across clinics, hospitals, pharmacies, and other channels. This integrated operating model gives the company several established routes to reach healthcare customers and support product expansion.
Bears Say
Persistent Net LossesRecurring EBIT and net losses show that the company has not yet converted its gross profitability into sustainable earnings. Continued losses can restrict internal investment, weaken resilience, and make future performance dependent on a successful improvement in operating economics.
Multi-Year Revenue ContractionSeveral years of declining revenue limit operating leverage and make fixed costs harder to absorb. Without a durable return to top-line growth, the company has less opportunity to spread expenses, improve profitability, or build a stronger earnings base over the next several quarters.
High And Worsening LeverageElevated leverage combined with declining equity reduces financial flexibility and increases the balance sheet’s sensitivity to continued losses. Negative returns on equity indicate that capital is not currently producing profits, limiting the company’s ability to fund growth from a stronger capital base.
PuraPharm Corp. Ltd. News
1498 FAQ
What was PuraPharm Corp. Ltd.’s price range in the past 12 months?
PuraPharm Corp. Ltd. lowest stock price was HK$0.23 and its highest was HK$0.44 in the past 12 months.
What is PuraPharm Corp. Ltd.’s market cap?
PuraPharm Corp. Ltd.’s market cap is HK$123.04M.
When is PuraPharm Corp. Ltd.’s upcoming earnings report date?
PuraPharm Corp. Ltd.’s upcoming earnings report date is Mar 31, 2027 which is in 151 days.
How were PuraPharm Corp. Ltd.’s earnings last quarter?
PuraPharm Corp. Ltd. released its earnings results on Aug 26, 2026. The company reported -HK$0.027 earnings per share for the quarter.
Is PuraPharm Corp. Ltd. overvalued?
According to Wall Street analysts PuraPharm Corp. Ltd.’s price is currently Overvalued.
Does PuraPharm Corp. Ltd. pay dividends?
PuraPharm Corp. Ltd. pays a Annually dividend of HK$0.019 which represents an annual dividend yield of 0.48%. See more information on PuraPharm Corp. Ltd. dividends here
What is PuraPharm Corp. Ltd.’s EPS estimate?
PuraPharm Corp. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PuraPharm Corp. Ltd. have?
PuraPharm Corp. Ltd. has 535,897,640 shares outstanding.
What happened to PuraPharm Corp. Ltd.’s price movement after its last earnings report?
PuraPharm Corp. Ltd. reported an EPS of -HK$0.027 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of PuraPharm Corp. Ltd.?
Currently, no hedge funds are holding shares in HK:1498
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PuraPharm Corp. Ltd.
PuraPharm Corporation Limited, an investment holding entity, focuses on the research, development, manufacturing, and global distribution of concentrated Chinese medicine granules (CCMG) and various Chinese healthcare products across Hong Kong, Mainland China, and international markets. Its operations are structured into five key divisions: China CCMG, Hong Kong CCMG, Chinese Healthcare Products, Clinics, and Plantation. The company offers a range of over-the-counter health solutions under brand names such as PuraGold, Haveron, Oncozac, and Immuzac. Beyond product sales, PuraPharm provides a clinic management system for general Chinese medical practices and operates its own chain of Nong's Chinese medicine clinics, which deliver both traditional medical services and CCMG products. The company also oversees the cultivation and trade of raw Chinese herbs, in addition to manufacturing and selling traditional Chinese medicine decoction pieces. Complementing its product offerings, it delivers modernized Chinese medicine services and diagnostic consultations. PuraPharm distributes its goods to hospitals, healthcare institutions, medical professionals, and directly to consumers via an online store. The company currently manages 43 Nong's clinics in Hong Kong and one in Guangxi, China. Founded in 1998, its headquarters are located in Tai Po, Hong Kong.
Technical Analysis
Extrawell Pharmaceutical Holdings Limited
―
Wai Yuen Tong Medicine Holdings Limited
―
Lee's Pharmaceutical Holdings Limited
―
Pak Fah Yeow International Limited
―
Golden Throat Holdings Group Co Ltd
―